XPAR
NANO
Market cap1.21bUSD
Oct 09, Last price
21.24EUR
1D
3.51%
1Q
-40.27%
Jan 2017
37.56%
IPO
216.07%
Name
Nanobiotix SA
Chart & performance
P/E
—
P/S
34.68
EPS
—
Div yield, %
—
Shrs. gr., 5y
14.42%
Rev. gr., 5y
66.38%
Revenues
30m
P
Net income
-24m
L-64.83%
CFO
-33m
L+70.95%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Nanobiotix S.A. is a clinical-stage biotechnology firm dedicated to advancing innovative therapeutic candidates for oncology. Its flagship experimental treatment, NBTXR3, is a sterile, water-based suspension composed of crystalline hafnium oxide nanoparticles. This compound is under investigation for its potential in addressing a wide array of cancers, including soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, and rectal cancers, along with non-small cell lung cancer. To facilitate the development and market entry of NBTXR3, Nanobiotix S.A. has formed a strategic partnership with LianBio, targeting Greater China, South Korea, Singapore, and Thailand. The company was founded in 2003 and its main operations are based in Paris, France.
Key people
Independent Chairman of the Supervisory Board · since 2021
Bart Van Rhijn
Chief Financial Officer, Member of the Management Board · since 2021
Anne-Juliette Hermant
Chief People Officer, Member of the Management Board · since 2019
Craig West
Senior Vice President - Investor Relations · since 2024
Anne-Sophie Lariviere
Vice President - Strategy & Operational Excellence
Brandon Owens
Vice President - Strategic Marketing and Corporate Communications
Louis Kayitalire
Chief Medical Officer · since 2023
Margaret Liu
Director · since 2024
Anat Naschitz
Director · since 2024
Independent Vice Chairwoman of the of the Board · since 2014
Independent Member of the Supervisory Board · since 2013
Independent Member of the Supervisory Board · since 2014
Headquarters & legal address
60 RUE DE WATTIGNIES
PARIS 75012
FR
PARIS 75012
FR
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||